EPS for Enanta Pharmaceuticals, Inc. (ENTA) Expected At $1.21

November 10, 2018 - By Peter Erickson

Investors sentiment decreased to 1.5 in 2018 Q2. Its down 0.16, from 1.66 in 2018Q1. It dropped, as 16 investors sold Enanta Pharmaceuticals, Inc. shares while 46 reduced holdings. 34 funds opened positions while 59 raised stakes. 14.64 million shares or 3.25% more from 14.18 million shares in 2018Q1 were reported.
D E Shaw And Inc stated it has 32,265 shares or 0% of all its holdings. Metropolitan Life Ins owns 5,474 shares or 0% of their US portfolio. Armistice Cap Ltd Liability Co invested in 124,000 shares. Moreover, Automobile Association has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 24,980 shares. Millennium Llc stated it has 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Credit Suisse Ag accumulated 30,643 shares. Geode Cap Management Ltd Liability Corp holds 0.01% or 170,398 shares in its portfolio. Ubs Asset Mngmt Americas Incorporated reported 10,815 shares. Pub Employees Retirement System Of Ohio invested in 0.01% or 19,575 shares. The New York-based American Interest Grp has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 1.10 million are held by Vanguard Grp Inc. Farallon Cap Management invested 0.77% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Cibc Markets invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 3,311 are held by Caxton Associate Limited Partnership. Amalgamated Retail Bank invested 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Since May 16, 2018, it had 0 insider purchases, and 8 selling transactions for $11.16 million activity. 15,000 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares with value of $1.81 million were sold by MELLETT PAUL J. Luly Jay R. sold $4.38M worth of stock.

Analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report $1.21 EPS on November, 19.They anticipate $0.65 EPS change or 34.95 % from last quarter’s $1.86 EPS. ENTA’s profit would be $23.45 million giving it 15.70 P/E if the $1.21 EPS is correct. After having $0.97 EPS previously, Enanta Pharmaceuticals, Inc.’s analysts see 24.74 % EPS growth. The stock decreased 2.81% or $2.2 during the last trading session, reaching $76.01. About 282,550 shares traded or 11.92% up from the average. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 110.33% since November 10, 2017 and is uptrending. It has outperformed by 94.71% the S&P500.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 2 analysts covering Enanta Pharmaceuticals (NASDAQ:ENTA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals had 4 analyst reports since May 24, 2018 according to SRatingsIntel. Oppenheimer initiated Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Thursday, June 7. Oppenheimer has “Buy” rating and $13500 target. Oppenheimer downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Wednesday, August 8 to “Perform” rating.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.47 billion. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 19.23 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

More important recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on October 26, 2018, also Nasdaq.com published article titled: “Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology …”, Seekingalpha.com published: “Enanta launches mid-stage study on RSV candidate EDP-938; shares up 4% premarket” on October 23, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was released by: Seekingalpha.com and their article: “Gilead In PBC: The Clinical Pursuit For Dominance” with publication date: October 15, 2018.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News